Literature DB >> 12757235

The prevalence of viral hepatitis among the Hmong people of northern Thailand.

S Louisirirotchanakul1, K S A Myint, B Srimee, C Kanoksinsombat, C Khamboonruang, P Kunstadter, Chantapong Wasi.   

Abstract

Sera from 269 Hmong people (102 males and 167 females, with mean age 35.4 years, range 16-63 years) were examined in order to determine the seroprevalence of hepatitis virus infection. The seroprevalence rates for HAV (hepatitis A virus), HBV (hepatitis B virus), HCV (hepatitis C virus), HDV (hepatitis D virus), HEV (hepatitis E virus), HGV (hepatitis G virus) and TTV (TT virus) infection were 87.8% (n=140), 76.0% (n=150), 2.0% (n=150), 0.7% (n=150), 6.5% (n=139), 5.3% (n=94) and 25.6% (n=121) respectively. The rate for carriers of HBV (HBsAg) was 13.8% (20.5% in males and 9.6% females) with a peak prevalence in the 21-40 year age group. A high rate of HAV seropositivity was found among the younger subjects. The rate of HEV seroprevalence was low. The prevalence of TTV-DNA was high with no difference between the sexes. HGV-RNA prevalence was low and seen primarily in males. This study indicates that the Hmong people are endemically infected with HAV and HBV infection and should be considered for targeted vaccination. The role of TTV and HGV in producing illness and hepatic disease has yet to be determined in this population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12757235

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  8 in total

1.  Chronic hepatitis B in Asian women of childbearing age.

Authors:  Nancy Leung
Journal:  Hepatol Int       Date:  2009-07-09       Impact factor: 6.047

2.  Prevalence of hepatitis B infection among young and unsuspecting Hmong blood donors in the Central California Valley.

Authors:  Muhammad Y Sheikh; Pradeep R Atla; Rahim Raoufi; Humaira Sadiq; Patrick C Sadler
Journal:  J Community Health       Date:  2012-02

Review 3.  Hepatitis D: Scenario in the Asia-Pacific region.

Authors:  Zaigham Abbas; Wasim Jafri; Sajjad Raza
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

4.  Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women.

Authors:  Woottichai Khamduang; Nicole Ngo-Giang-Huong; Catherine Gaudy-Graffin; Gonzague Jourdain; Weerapong Suwankornsakul; Tapnarong Jarupanich; Veeradate Chalermpolprapa; Sirisak Nanta; Noossara Puarattana-Aroonkorn; Sakchai Tonmat; Marc Lallemant; Alain Goudeau; Wasna Sirirungsi
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

5.  Prevalence of hepatitis B virus (HBV) infection among Hmong immigrants in the San Joaquin Valley.

Authors:  Muhammad Y Sheikh; Mouatou Mouanoutoua; Matthew D Walvick; Leepao Khang; Jasjit Singh; Steven Stoltz; Paul K Mills
Journal:  J Community Health       Date:  2011-02

6.  Swine is a possible source of hepatitis E virus infection by comparative study of hepatitis A and E seroprevalence in Thailand.

Authors:  Pattaratida Sa-nguanmoo; Nawarat Posuwan; Preeyaporn Vichaiwattana; Norra Wutthiratkowit; Somchai Owatanapanich; Rujipat Wasitthankasem; Thanunrat Thongmee; Kittiyod Poovorawan; Apiradee Theamboonlers; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

7.  Prevalence of hepatitis D virus in hepatitis B virus infected patients referred to Taleghani hospital, Tehran, Iran.

Authors:  Seyed Mohammad Ebrahim Tahaei; Seyed Reza Mohebbi; Pedram Azimzadeh; Abbas Behelgardi; Azar Sanati; Parvaneh Mohammadi; Mahsa Khanyaghma; Armin Hosseini Razavi; Afsaneh Sharifian; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2014

8.  Histological and Serological Epidemiology of Hepatitis Delta Virus Coinfection among Patients with Chronic Active Hepatitis B Virus in Razavi Khorasan Province, Northeastern Iran.

Authors:  Payam Sharifan; Sakineh Amoueian
Journal:  Iran J Public Health       Date:  2018-12       Impact factor: 1.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.